RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

November 17, 2017: By Jon Swedien

RegeneRx Biopharmaceuticals’ proposed dry eye treatment, RGN-259, showed statistically significant improvement over placebo in its ARISE-2 Phase III clinical study, the Rockville, Maryland company reported Oct. 31.

RGN-259, a Thymosin beta 4 (Tβ4)-based sterile and preservative-free eye drop, is as a novel treatment candidate for dry eye and neurotrophic keratitis (NK), and other corneal diseases, RegeneRx said.

The ARISE-2 trial was sponsored by ReGenTree, a US joint venture company owned by GtreeBNT, a bio venture company in South Korea, and RegeneRx.

The trial investigated the safety and efficacy of RGN-259 for the treatment of the signs and symptoms of dry eye syndrome in 601 patients.

RGN-259 (0.1%) demonstrated a number of statistically significant improvements in both signs and symptoms, while showing excellent safety, comfort, and tolerability profiles, ReGenTree said.

For example, the RGN-259-treated group saw a statistically significant reduction in ocular discomfort at day 15 compared with placebo (p=0.0149) in a change from baseline, ReGenTree said.

ReGenTree president and CEO Won S. Yang said the company plans to meet with the US FDA to discuss the ARISE-2 findings.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

Allergan Appoints Matthew Walsh as CFO

Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023